The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 2913296 |
4 |
Cardiotonic agents. 1-Methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3 (2H)-isoquinolinones and related compounds. Synthesis and activity. |
Mitsui Toatsu Chemicals |
| 10636238 |
71 |
Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors. |
Institut De Recherche Jouveinal-Parke Davis |
| 27597413 |
58 |
Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings. |
Southern Medical University |
| 27301679 |
21 |
Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket. |
Takeda Pharmaceutical |
| 26526739 |
35 |
Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships. |
Southern Medical University |
| 25815146 |
29 |
Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors. |
Janssen Pharmaceutica |
| 25801159 |
36 |
Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5. |
Csir-Indian Institute Of Integrative Medicine |
| 25221665 |
33 |
Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement. |
Janssen Pharmaceutica |
| 15887951 |
29 |
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. |
Monash University (Parkville Campus) |
| 10090791 |
77 |
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives. |
Tanabe Seiyaku |
| 8254606 |
55 |
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline. |
Eisai |
| 2822927 |
51 |
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity. |
Warner-Lambert |
| 2985781 |
53 |
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. |
TBA |
| 12824030 |
67 |
1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors. |
Tanabe Seiyaku |
| 11755362 |
24 |
Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor. |
Novartis Pharma |
| 22142545 |
96 |
Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia. |
Merck Research Laboratories |
| 21955943 |
47 |
Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region. |
Pfizer |
| 20196613 |
32 |
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5). |
Pfizer |
| 19631533 |
126 |
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one. |
Pfizer |
| 1955879 |
2 |
Bisbenzylisoquinoline Alkaloids |
TBA |
| | 71 |
Imidazotriazinone inhibitors of the Ca2+-calmodulin sensitive phosphodiesterase (PDE I) |
TBA |
| 19339180 |
69 |
The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. |
Pfizer |
| 19303290 |
4 |
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. |
Anacor Pharmaceuticals |
| 16337379 |
14 |
Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution. |
Sumitomo Pharmaceuticals |
| 16275071 |
26 |
A new chemical tool for exploring the physiological function of the PDE2 isozyme. |
Pfizer |
| 16005625 |
162 |
Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5. |
Sumitomo Pharmaceuticals |
| 15993055 |
61 |
Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors. |
Bayer Healthcare |
| 15324877 |
90 |
Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives. |
Pfizer |
| 15324876 |
94 |
Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1. |
Pfizer |
| 15324874 |
169 |
Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies. |
Pfizer |
| 15149695 |
24 |
New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. |
Pfizer |
| 10197972 |
133 |
1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor. |
Tanabe Seiyaku |
| 9873594 |
44 |
Aryl sulfonamides as selective PDE4 inhibitors. |
Chiroscience |
| 6471063 |
10 |
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. |
TBA |
| 3585900 |
10 |
Cardiotonic agents. 5. 1,2-Dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-6-methyl-2-oxo-3- pyridinecarbonitriles and related compounds. Synthesis and inotropic activity. |
TBA |
| 2822926 |
95 |
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activi |
Warner-Lambert |
| 17507218 |
28 |
Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model. |
Abbott Laboratories |
| 11591522 |
17 |
Structure-based design of caspase-1 inhibitor containing a diphenyl ether sulfonamide. |
Pfizer |
Search and Browse
